Table 1 Comparison of clinical and pathological data in two groups (n, %)

Gender

Male

54

26

86.67

28

93.33

Female

6

4

13.33

2

6.67

Age (years)

>60

24

11

36.67

13

43.33

0.278

≤ 60

36

19

63.33

17

56.67

Staging

(in

second-line)

IIIB

5

3

10.00

2

6.67

0.508

IVA

9

5

16.67

4

13.33

IVB

46

22

73.33

24

80.00

T Stage

0

23

11

36.67

12

40.00

0.316

2

4

2

6.67

2

6.67

3

27

14

46.67

13

43.33

4

6

3

10.00

3

10.00

N Stage

0

9

5

16.67

4

13.33

1.766

1

15

9

30.00

6

20.00

2

9

3

10.00

6

20.00

3

27

13

43.33

14

46.67

M Stage

0

15

9

30.00

6

20.00

0.800

1

45

21

70.00

24

80.00

Location

Upper

8

4

13.33

4

13.33

0.181

Middle

35

17

56.67

18

60.00

Lower

17

9

30.00

8

26.67

Differentiation

Poor

7

6

20.00

1

3.33

4.401

Moderate

51

23

76.67

28

93.33

Well

2

1

3.33

1

3.33

Prior Radical Surgery

Yes

27

11

36.67

16

53.33

1.684

No

33

19

63.33

14

46.67

Prior Radical Chemoradiotherapy

Yes

16

11

36.67

5

16.67

3.068

No

44

19

63.33

25

83.33

Dose Reduction Due to AEs

Yes

10

3

10.00

7

23.33

1.920

No

50

27

90.00

23

76.67

Discontinuation Due to AEs

Yes

15

9

30.00

6

20.00

0.800

No

45

21

70.00

24

80.00

First-line chemotherapy regimen

Taxane combined with platinum

42

21

70.00

21

70.00

2.940

Fluoropyrimidine combined with platinum

12

5

16.67

7

23.33

Paclitaxel

1

0

0.00

1

3.33

Fluoropyrimidine

5

4

13.33

1

3.33

Second-line chemotherapy regimen

Fluoropyrimidine ± platinum

22

14

46.67

8

26.67

5.818

Irinotecan ± fluoropyrimidine

16

4

13.33

12

40.00

Taxane ± platinum

22

12

40.00

10

33.33

third-line and beyond

No

28

17

56.67

11

36.67

5.191

Third-line

18

6

20.00

12

40.00

Fourth-line

10

5

16.67

5

16.67

Fifth-line

4

2

6.67

2

6.67